Should You Invest In Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) In 2024?

In the last trading session, 1.24 million Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) shares changed hands as the company’s beta touched 0.73. With the company’s per share price at $32.26 changed hands at -$0.3 or -0.92% during last session, the market valuation stood at $4.00B. ARWR’s last price was a discount, traded about -31.68% off its 52-week high of $42.48. The share price had its 52-week low at $20.67, which suggests the last value was 35.93% up since then. When we look at Arrowhead Pharmaceuticals Inc.’s average trading volume, we note the 10-day average is 1.3 million shares, with the 3-month average coming to 0.78.

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) trade information

Instantly ARWR was in red as seen at the end of in last trading. With action 0.75%, the performance over the past five days has been green. The drop to weekly highs of 33.30 subtracted -0.92% to the stock’s daily price. The company’s shares are showing year-to-date upside of 5.42%, with the 5-day performance at 0.75% in the green. However, in the 30-day time frame, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) is -13.97% down. Looking at the short shares, we see there were 7.72 million shares sold at short interest cover period of 4.05 days.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Arrowhead Pharmaceuticals Inc. (ARWR) estimates and forecasts

Data shows that the Arrowhead Pharmaceuticals Inc. share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 11.82% over the past 6 months, a -43.23% in annual growth rate that is considerably lower than the industry average of 11.60%. Moreover, analysts have looked to lower expectations by upgrading its fiscal year 2024 revenue estimates. The rating firms predict current quarter revenue for Arrowhead Pharmaceuticals Inc. will fall -148.90%, while the growth in revenue is estimated to hit 31.20% for the next quarter. Year-over-year growth is forecast to reach -43.90% down from the last financial year.

Consensus estimates given by 11 financial analysts project the company’s revenue in the current quarter to hit an average of $59.93 million. 11 analysts are of the opinion that Arrowhead Pharmaceuticals Inc.’s revenue for the quarter ending Jun 2024 will be $26.84 million.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -24.19%. The 2024 estimates are for Arrowhead Pharmaceuticals Inc. earnings to decrease by -40.82%, but the outlook for the next 5-year period is at 7.33% per year.

ARWR Dividends

Arrowhead Pharmaceuticals Inc. is expected to release its next quarterly earnings report between April 30 and May 06.

On Key

Related Posts